Non-small cell lung cancer, breast cancer, colorectal cancer, and nasopharyngeal cancer patients with tumors expressing high levels of LIF exhibit a shorter overall survival8–10 indicating that high LIF expression might be involved in the oncogenic progression of these malignancies. This evidence concerns the gene LIF and breast carcinoma.